资源描述
前列腺癌 ASCO,1,1. 多西他赛：E3805 (CHAARTED)与STAMPEDE2.生化复发的挽救治疗：GETUG-AFU163.转移性前列腺癌间断或持续雄激素剥夺治疗的长期结果4. PAS升高前列腺癌ADT干预时机：2个期随机临床试验联合分析,主要内容,2,1. 多西他赛：E3805 (CHAARTED)与STAMPEDE2.生化复发的挽救治疗：GETUG-AFU163.转移性前列腺癌间断或持续雄激素剥夺治疗的长期结果4. PAS升高前列腺癌ADT干预时机：2个期随机临床试验联合分析,主要内容,3,E3805 (CHAARTED)：研究设计,Sweeney C, et al. 2014 ASCO Abstract LBA2.,4,E3805 (CHAARTED)：主要入组标准,转移性前列腺癌既往抗雄治疗，限于：随机前12天或辅助治疗 Combined with Group 1 for analysis,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,74,Primary endpoint: overall survival,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,75,Primary endpoint: overall survival,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,76,Primary endpoint: overall survival,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,77,Cause-specific survival,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,78,Overall survival by ADT schedule,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,79,Other disease endpoints,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,80,Time to first prostate cancer complication,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,出现前列腺癌并发症时间,81,ADT-related symptoms,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,ADT相关症状 A组：89人接受了ADT，61人没接受 34.7%在前2年 16.7%在2-4年间 8.0%在4年后 40.6%在研究期间未开始ADT ADT平均开始时间18.7月 A组：47.3%报告了ADT相关症状，52.7%无 B组：77.9%报告了ADT相关症状，22.1%无,82,Conclusions,Presented By Gillian Duchesne at 2015 ASCO Annual Meeting,结论 本试验提供中等证据：对于初治或非治愈性前列腺癌PSA复发立即进行ADT可以改善5年的OS约10% 立即组前列腺癌并发症发生率低且晚 因为这是一种非治愈性手段，因此，获益必须考虑ADT治疗相关并发症的发生率（立即组80%，延迟组50%）,83,谢谢！,84,
展开阅读全文